EGFR S442 ectodomain mutation confers cetuximab resistance that can be overcome by ERBB2 blockade with trastuzumab-deruxtecan. Harmych SJ, Joshi N, Tanaka H, Bogatcheva G, et al. Cancer Lett 2026;654:218607.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Harmych SJ, Joshi N, Tanaka H, Bogatcheva G, et al. EGFR S442 ectodomain mutation confers cetuximab resistance that can be overcome by ERBB2 blockade with trastuzumab-deruxtecan. Cancer Lett 2026;654:218607.
PMID: 42176792